Evidence map›Paper›PMID 40459012›Full record

ArticleEuropean journal of haematology2025

Sensitization of Non-M3 Acute Myeloid Leukemia Blasts to All-Trans Retinoic Acid by the LSD1 Inhibitor Tranylcypromine: TRANSATRA Phase I Study.

Michael Kruszewski, Claudia Schmoor, Tobias Berg, Usama-Ur Rehman, Marcus Schittenhelm, Katharina Götze, Andrea Kündgen, Caroline Pabst, Tobias Ma, Anna Frey and 13 more

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Michael KruszewskiDepartment of Hematology, Oncology and Stem Cell Transplantation, Medical Center-University of Freiburg, Freiburg, Germany.ORCID https://orcid.org/0009-0008-6785-5747
Claudia SchmoorClinical Trials Unit, Medical Center-University of Freiburg, Freiburg, Germany.
Tobias BergCentre for Discovery in Cancer Research, Department of Oncology, McMaster University, Hamilton, Ontario, Canada.
Usama-Ur RehmanDepartment of Hematology, Oncology and Stem Cell Transplantation, Medical Center-University of Freiburg, Freiburg, Germany.
Marcus SchittenhelmDepartment of Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
Katharina GötzeMedical Department of Hematology and Oncology, Technical University of Munich, Klinikum Rechts der Isar, Munich, Germany.
Andrea KündgenDepartment of Hematology, Oncology and Clinical Immunology, Düsseldorf University Hospital, Düsseldorf, Germany.
Caroline PabstDepartment of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
Tobias MaDepartment of Hematology, Oncology and Stem Cell Transplantation, Medical Center-University of Freiburg, Freiburg, Germany.
Anna FreyDepartment of Pathology, Medical Center-University of Freiburg, Freiburg, Germany.
Julia StomperDepartment of Hematology, Oncology and Stem Cell Transplantation, Medical Center-University of Freiburg, Freiburg, Germany.
Dietmar PfeiferDepartment of Hematology, Oncology and Stem Cell Transplantation, Medical Center-University of Freiburg, Freiburg, Germany.
Eric MetzgerGerman Cancer Consortium (DKTK), Freiburg, Germany.
Johannes JungDepartment of Hematology, Oncology and Stem Cell Transplantation, Medical Center-University of Freiburg, Freiburg, Germany.
Kevin MoschallskiDepartment of Hematology, Oncology and Stem Cell Transplantation, Medical Center-University of Freiburg, Freiburg, Germany.
Johanna ThomasDepartment of Hematology, Oncology and Stem Cell Transplantation, Medical Center-University of Freiburg, Freiburg, Germany.
Gesine BugDepartment of Medicine II, Hematology/Oncology, Goethe University, Frankfurt/Main, Germany.
Justus DuysterDepartment of Hematology, Oncology and Stem Cell Transplantation, Medical Center-University of Freiburg, Freiburg, Germany.
Manfred JungGerman Cancer Consortium (DKTK), Freiburg, Germany.
Roland SchüleGerman Cancer Consortium (DKTK), Freiburg, Germany.
Ralph WäschDepartment of Hematology, Oncology and Stem Cell Transplantation, Medical Center-University of Freiburg, Freiburg, Germany.
Olga GrishinaClinical Trials Unit, Medical Center-University of Freiburg, Freiburg, Germany.
Michael LübbertDepartment of Hematology, Oncology and Stem Cell Transplantation, Medical Center-University of Freiburg, Freiburg, Germany.

Funding

Deutschen Konsortium für Translationale Krebsforschung
6 · The paper itself

Abstract

The treatment of elderly, nonfit acute myeloid leukemia (AML)/MDS patients with relapsed/refractory (R/R) disease remains challenging. As histone demethylase LSD1 (KDM1A) is a rational therapeutic target in AML, we conducted a phase I trial ("rolling-six design") with the LSD1 inhibitor tranylcypromine (TCP, dose levels [DL] 20, 40, 60, 80 mg p.o. d1-28) combined with fixed-dose ATRA (45 mg/m

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBlast CrisisHistone DemethylasesLeukemia, Myeloid, AcuteTranylcypromineTretinoinAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedTreatment OutcomeHistone DemethylasesKDM1A protein, humanTranylcypromineTretinoinCD38chromatindifferentiationhistone demethylaseLSD1myelodysplastic syndrome

Identifiers

PMID40459012
PMCPMC12319880

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.